AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
24/7 Wall St. on MSN4d
AbbVie Just Paid Investors: Here’s How Much They ReceivedAbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.
3don MSN
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
GlobalData on MSN5d
AbbVie and Xilio to collaborate on antibody-based immunotherapiesAbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
The stock's fall snapped a two-day winning streak.
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback